TY  - JOUR
AB  - Cancer is an important cause of morbidity and mortality worldwide. Advances in research on the biology of cancer revealed alterations in several key pathways underlying tumorigenesis and provided molecular targets for developing new and improved existing therapies. Syndecan-4, a transmembrane heparan sulfate proteoglycan, is a central mediator of cell adhesion, migration and proliferation. Although several studies have demonstrated important roles of syndecan-4 in cell behavior and its interactions with growth factors, extracellular matrix (ECM) molecules and cytoskeletal signaling proteins, less is known about its role and expression in multiple cancer. The data summarized in this review demonstrate that high expression of syndecan-4 is an unfavorable biomarker for estrogen receptor-negative breast cancer, glioma, liver cancer, melanoma, osteosarcoma, papillary thyroid carcinoma and testicular, kidney and bladder cancer. In contrast, in neuroblastoma and colorectal cancer, syndecan-4 is downregulated. Interestingly, syndecan-4 expression is modulated by anticancer drugs. It is upregulated upon treatment with zoledronate and this effect reduces invasion of breast cancer cells. In our recent work, we demonstrated that the syndecan-4 level was reduced after trastuzumab treatment. Similarly, syndecan-4 levels are also reduced after panitumumab treatment. Together, the data found suggest that syndecan-4 level is crucial for understanding the changes involving in malignant transformation, and also demonstrate that syndecan-4 emerges as an important target for cancer therapy and diagnosis.
AU  - Onyeisi, Jessica Oyie Sousa
AU  - Lopes, Carla Cristina
AU  - Götte, Martin
DA  - 2021-03-26
DO  - 10.17879/12099604117
KW  - syndecan-4
KW  - heparan sulfate
KW  - cancer
KW  - prognosis
KW  - biomarker
KW  - signal transduction
KW  - proteoglycan
KW  - metastasis
LA  - eng
N1  - Biomolecules 11 (2021) 4, 503, 1-16
N1  - Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).
PY  - 2021-03-26
TI  - Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer
UR  - https://nbn-resolving.org/urn:nbn:de:hbz:6-52089560060
Y2  - 2024-11-22T02:35:56
ER  -